Canaccord analyst Whitney Ijem raised the firm’s price target on Alnylam (ALNY) to $385 from $384 and keeps a Buy rating on the shares. The firm said its 4Q24 report was uneventful following its preannouncement earlier in the year. Focus remains on the upcoming Amvuttra label expansion in ATTR-CM and the “will they/won’t they” on a potential price drop as they expand into the much larger CM indication which Canaccord assumes will be a price drop.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Hold Rating Due to Stable Financials and Uncertain Pipeline Prospects
- Alnylam Pharmaceuticals’ Earnings Call Highlights Strong Growth
- Alnylam price target lowered to $300 from $310 at Scotiabank
- Strong Buy Recommendation for Alnylam Pharma Amid Upcoming PDUFA Date and Promising Growth Prospects
- Alnylam Pharmaceuticals Reports Strong 2024 Growth